Stratum Market Research
Contact

Healthcare ranking

Top 25 cancer clinical trial sponsors 2026

Jiangsu Hengrui Pharmaceuticals started the most cancer clinical trials as lead sponsor between November 2023 and October 2026, with 174 trials. The list ranks companies worldwide by the number of new interventional trials they lead in this area.

  • Measurenew industry-sponsored clinical trials
  • PeriodNovember 2023 to October 2026
  • Ranked25 companies
  • Updated10 Nov 2026

Top 10 at a glance

  1. Jiangsu Hengrui Pharmaceuticals174 trials
  2. AstraZeneca114 trials
  3. Sichuan Baili Pharmaceutical (Biokin)106 trials
  4. Merck & Co. (MSD)101 trials
  5. Chia Tai Tianqing (Sino Biopharm)86 trials
  6. CSPC Pharmaceutical Group72 trials
  7. Bristol Myers Squibb60 trials
  8. Johnson & Johnson (Janssen)59 trials
  9. Qilu Pharmaceutical58 trials
  10. Pfizer55 trials

The full list

RankCompanyHeadquartersnew industry-sponsored clinical trials (trials)
1Jiangsu Hengrui PharmaceuticalsChina174
2AstraZenecaUnited Kingdom114
3Sichuan Baili Pharmaceutical (Biokin)China106
4Merck & Co. (MSD)United States101
5Chia Tai Tianqing (Sino Biopharm)China86
6CSPC Pharmaceutical GroupChina72
7Bristol Myers SquibbUnited States60
8Johnson & Johnson (Janssen)United States59
9Qilu PharmaceuticalChina58
10PfizerUnited States55
11Hansoh PharmaceuticalChina50
12AbbVieUnited States49
13AkesoChina48
14GSKUnited Kingdom46
15NovartisSwitzerland44
16BeOne Medicines (BeiGene)Switzerland42
16Shanghai Henlius BiotechChina42
18RocheSwitzerland41
19Kelun-BiotechChina33
20AmgenUnited States32
20Eli LillyUnited States32
22Daiichi SankyoJapan31
22Beijing BiotechChina31
22RegeneronUnited States31
25Innovent BiologicsChina30

How this list is built

We counted interventional clinical trials with a company as lead sponsor and a start date from 1 November 2023 to 31 October 2026 that list cancer as a studied condition; withdrawn trials are not counted. Subsidiaries and name variants are merged into the parent company ("Suzhou Suncadia Biopharmaceuticals Co., Ltd." and "Jiangsu HengRui Medicine Co., Ltd." are counted as Jiangsu Hengrui Pharmaceuticals), and hospitals, universities and other non-company sponsors are left out. Companies with the same count share a rank, and all companies tied at the last place are shown.

Every position is set by the data alone, by the same rules for every company. Spotted something to update? Write to info@stratummarketresearch.com with the list and the line, and we correct it within two working days.

For ranked companies: a free badge

Ranked companies can show this badge on their website, in a press release or on LinkedIn at no cost. Pick your company, then copy the code.

Ranking badge preview

Frequently asked questions

Who is number one in the cancer clinical trial sponsors ranking?

Jiangsu Hengrui Pharmaceuticals ranks first with 174 trials (November 2023 to October 2026).

How is this ranking calculated?

We counted interventional clinical trials with a company as lead sponsor and a start date from 1 November 2023 to 31 October 2026 that list cancer as a studied condition; withdrawn trials are not counted. Subsidiaries and name variants are merged into the parent company ("Suzhou Suncadia Biopharmaceuticals Co., Ltd." and "Jiangsu HengRui Medicine Co., Ltd." are counted as Jiangsu Hengrui Pharmaceuticals), and hospitals, universities and other non-company sponsors are left out. Companies with the same count share a rank, and all companies tied at the last place are shown.

Can a company pay to rank higher?

Positions come only from the counts described above, and inclusion is free. Every company is ranked by the same rules.

How often is the ranking updated?

Every list is recomputed each quarter from the latest public records, and the update date is printed on the page.

Can a ranked company use the badge?

Yes. Every ranked company can use the free web badge on this page on its website, in press releases and on social media.

Custom research

Looking for a specific market?

Tell us the market, the region and the decision you are making. We reply within one working day with a scope and a date.